Key result
Pluripotent stem cell-derived cardiomyocytes show promise for modeling drug targets and chemotherapy cardiotoxicity.
Why the study?
Novel cardioprotective therapies are needed to improve clinical outcomes in cancer patients experiencing chemotherapy-induced cardiomyopathy, requiring appropriate experimental models for testing.
Answers are grounded in this paper and cite their sources.
Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Madonna et al. (2016) conducted a review in Chemotherapy-induced cardiomyopathy. iPS- and hESC-derived cardiomyocytes was evaluated. Induced pluripotent stem cell- and human embryonic stem cell-derived cardiomyocytes serve as promising in vitro models for evaluating pharmacological targets and predicting chemotherapy cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: